This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Faris, O. P. Articles by Shein, M. Search for Related Content PubMed PubMed Citation Articles by Faris, O. P. Articles by Shein, M. Related Collections Other Ethics and Policy Pacemaker Ablation/ICD/surgery CT and MRI Computerized tomography and Magnetic Resonance Imaging

(Circulation. 2006;114:1232-1233.)
© 2006 American Heart Association, Inc.

Editorial

Food and Drug Administration Perspective

Magnetic Resonance Imaging of Pacemaker and Implantable Cardioverter-Defibrillator Patients

Owen P. Faris, PhD; Mitchell Shein, MS

From the Division of Cardiovascular Devices, Center for Devices and Radiological Health, Food and Drug Administration, Rockville, Md.

Correspondence to Mitchell J. Shein, MS, FDA Expert, Cardiac Pacing, Division of Cardiovascular Devices, Center for Devices and Radiological Health, Food and Drug Administration, 9200 Corporate Boulevard, Rockville, MD 20850. E-mail mitchell.shein@fda.hhs.gov

Key Words: Editorials • defibrillation • imaging • magnetic resonance imaging • pacemakers • pacing

An extract of the first 250 words of the full text is provided, because this article has no abstract.

In April 2005, the US Food and Drug Administration (FDA) commented on the current research regarding the use of magnetic resonance imaging (MRI) on patients with a pacemaker or implantable cardioverter-defibrillator (ICD).¹ Pacemaker and ICD labeling currently cautions physicians against the use of MRI, and MRI manufacturers contraindicate MRI for pacemaker and ICD patients. As discussed in our previous editorial, several studies have demonstrated the potential for MRI to be performed in pacemaker or ICD patients without serious clinical consequence.^2–4 Studies presented by Sommer et al⁵ and Nazarian et al⁶ in this issue of Circulation offer further promising evidence in this regard. As with the previous studies, however, the authors acknowledge a multitude of limitations that prevent broad applicability of the results. Furthermore, one of these studies was not entirely free from concerning outcomes with the potential for serious clinical events. We view these results as consistent with our previous message that, on a case-by-case basis, the diagnostic benefit from MRI outweighs the presumed risks for some pacemaker and ICD patients. However, the FDA remains firm in its belief that those risks have not yet been characterized and mitigated sufficiently to justify the routine use of MRI in those populations. The FDA continues to believe that a more thorough evaluation of concerns related to heating, arrhythmogenesis, and proper device function during and after MRI, as well as validated MR protocols, should be available before approval for labeling that endorses the use of MRI for pacemaker or ICD patients is obtained.

. . . [Full Text of this Article]

This article has been cited by other articles:

				A. Roguin Magnetic resonance imaging in patients with implantable cardioverter-defibrillators and pacemakers. J. Am. Coll. Cardiol., August 4, 2009; 54(6): 556 - 557. [Full Text] [PDF]

				E. M. Aliot, W. G. Stevenson, J. M. Almendral-Garrote, F. Bogun, C. H. Calkins, E. Delacretaz, P. D. Bella, G. Hindricks, P. Jais, M. E. Josephson, et al. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: Developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA) Europace, June 1, 2009; 11(6): 771 - 817. [Full Text] [PDF]

				C. P. Naehle, C. Meyer, D. Thomas, S. Remerie, C. Krautmacher, H. Litt, R. Luechinger, R. Fimmers, H. Schild, and T. Sommer Safety of Brain 3-T MR Imaging with Transmit-Receive Head Coil in Patients with Cardiac Pacemakers: Pilot Prospective Study with 51 Examinations Radiology, December 1, 2008; 249(3): 991 - 1001. [Abstract] [Full Text] [PDF]

				T Dill Contraindications to magnetic resonance imaging Heart, July 1, 2008; 94(7): 943 - 948. [Full Text] [PDF]

				A. Roguin, J. Schwitter, C. Vahlhaus, M. Lombardi, J. Brugada, P. Vardas, A. Auricchio, S. Priori, and T. Sommer Magnetic resonance imaging in individuals with cardiovascular implantable electronic devices Europace, March 1, 2008; 10(3): 336 - 346. [Abstract] [Full Text] [PDF]

				T. Dickfeld, P. Lei, V. Dilsizian, J. Jeudy, J. Dong, A. Voudouris, R. Peters, M. Saba, R. Shekhar, and S. Shorofsky Integration of three-dimensional scar maps for ventricular tachycardia ablation with positron emission tomography-computed tomography. J. Am. Coll. Cardiol. Img., January 1, 2008; 1(1): 73 - 82. [Abstract] [Full Text] [PDF]

				G. N. Levine, A. S. Gomes, A. E. Arai, D. A. Bluemke, S. D. Flamm, E. Kanal, W. J. Manning, E. T. Martin, J. M. Smith, N. Wilke, et al. Safety of Magnetic Resonance Imaging in Patients With Cardiovascular Devices: An American Heart Association Scientific Statement From the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention: Endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance Circulation, December 11, 2007; 116(24): 2878 - 2891. [Abstract] [Full Text] [PDF]